Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

Ervaxx and Cardiff University Enter Collaboration to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigenstm


LONDON, Jan. 24, 2020 /PRNewswire/ -- Ervaxxtm, a biotechnology company pioneering the use of Dark Antigenstm to develop T-cell receptor (TCR)-based immunotherapies and off-the-shelf cancer vaccines, has entered a licensing and research collaboration with a leading T-cell immunology group at Cardiff University (Cardiff, UK).

The new collaboration will support a multi-year research program with Prof. Andrew Sewell's T-cell modulation group at Cardiff University focusing on the discovery and characterization of T-cells and TCRs reactive to cancer-specific antigens and ligands, including Ervaxx' proprietary Dark Antigenstm. Ervaxx will fund the program.

The collaboration will also advance exciting new research published earlier this week by the Cardiff University team in Nature Immunology1, where they identified a T cell clone that recognized and killed multiple different types of human cancer, while remaining inert to non-cancerous cells. The T cell clone targets MR1, an MHC class 1-related protein, via an unidentified cancer-specific ligand. These exciting findings, validated in a preclinical model, open the prospect of immunotherapies with broad utility across patients with diverse cancers. This approach into previously unexplored cell surface epitopes complements and extends Ervaxx's exploration of novel cancer-specific antigens.

Under the agreement, Ervaxx gains an exclusive license to relevant Cardiff University patents claiming T cells and TCRs reactive to cancer-specific antigens. The Company has the right to advance resulting candidate T-cell/TCR-based immunotherapeutics and cancer vaccines through development and commercialization. Cardiff University is eligible to receive milestone payments on any candidates that advance from the discovery collaboration into clinical development and royalty payments on sales of any products that reach the market.

Prof. Andrew Sewell, Head of the T-cell modulation group, Cardiff University, commented:

"Ervaxx's Dark Antigens, which are derived from the 98% of the genome that does not encode known proteins, constitute a promising and yet untapped source of targets for immunotherapies. This collaboration will use our world-class expertise in T-cell biology to identify T cells and TCRs reactive to those targets and pave the way for a new wave of treatments in cancer, and potentially other areas. This includes our most recent discovery, published in Nature Immunology, of a T-cell clone that targets MR1 to recognize and kill cancer cells, irrespective of cancer or human leukocyte antigen (HLA) type, offering opportunities for pan-cancer, pan-population cancer immunotherapies."

Kevin Pojasek, CEO of Ervaxx, said:

"We are excited to announce this collaboration with Prof. Sewell's world-class research group. We have great hope that through the combination of this expertise with our Dark Antigenstm and application of our EDAPTtm platform, we will be able to identify further targets to expand our portfolio of TCR-based therapies and cancer vaccines. We are also thrilled to contribute to the development of the group's exciting new MR1 research, which shows early but enormous potential for the treatment of cancers. This partnership, which follows those with the University of Oxford, University of Cambridge and Johns Hopkins University School of Medicine, reinforces our ambition to collaborate with leading academic institutions and be at the cutting edge  of the T-cell immunology field to drive the development of novel off-the-shelf cancer therapies."

Prof. Andrew Sewell is a member of Ervaxx' Scientific Advisory Board.

About Ervaxxtm

Ervaxx is pioneering the use of Dark Antigenstm to deliver targeted immunotherapies for treating and preventing cancer. Ervaxx Dark Antigens derive from vast untapped expanses of genetic 'dark matter' beyond the normal coding regions of the genome, which are generally silenced in normal tissue but can become selectively activated in cancer.

Ervaxx' powerful, proprietary EDAPTtm platform has been developed to discover and validate Dark Antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. The EDAPT platform has identified proprietary antigens that map to multiple solid tumor types and generate robust, antigen-specific T-cell responses. Ervaxx is advancing a pipeline of T cell receptor (TCR)-based therapies, off-the-shelf cancer vaccines and other immunotherapies leveraging these insights into the role of Dark Antigens in cancer.

Ervaxx was co-founded by SV Health Investors and is based on pioneering research at the Francis Crick Institute (London, UK). The company has offices in London, UK and a laboratory in the Bioescalator Building at Oxford University, UK. Ervaxx also has a strategic partnership with a global pharmaceutical company.

For more information visit: www.ervaxx.com 

Ervaxxtm, Dark Antigentm and EDAPTtm are trademarks of Ervaxx Limited

About the T-cell Modulation Group, Cardiff University

Cardiff University T-cell modulation group, within the Division of Infection and Immunity, consists of 16 researchers with a diverse skill and knowledge base that covers all areas of T-cell biology including T-cell genetics, molecular biology, protein chemistry, crystallography, and cell biology. The overall goal of the T-cell modulation group is to understand the genetic, biochemical and cellular mechanisms that govern T-cell responses to human disease. Our research outputs are extremely wide ranging and include basic studies which are aimed at understanding how the T-cell immune response is regulated, through to translational studies which are aimed at developing tools, diagnostics and treatments for human diseases such as cancer, HIV, EBV, tuberculosis and many more.

For More Information

Ervaxx Limited
Kevin Pojasek, CEO
Tel:  +44-(0)-186-561-8828
Email: info@ervaxx.com

Citigate Dewe Rogerson
Mark Swallow, Frazer Hall, Nathaniel Dahan
Tel: +44-(0)-20-7638-9571
Email: ervaxx@citigatedewerogerson.com

1 Crowther, M.D., Dolton, G., Legut, M. et al. Genome-wide CRISPR?Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nat Immunol (2020) doi:10.1038/s41590-019-0578-8

SOURCE Ervaxx


These press releases may also interest you

at 22:00
A January 18 article on Yahoo Sports reports on the gruesome injury that Las Vegas Golden Knights center Paul Stastny sustained as he was hit in the face with a high stick, knocking out several of his teeth and dispersing enough blood to warrant the...

at 20:00
Cybersecurity specialists hired by NCH recently wrapped up their investigation into an email phishing attack against NCH.  On or around June 14, 2019, NCH became aware of suspicious activity related to its human resources, timekeeping, and payroll...

at 19:20
Dental 3D Printing Market ? Scope of the Study The analyst recalibrated the growth potential of the dental 3D printing market in an exclusive research report, and unveiled some distinguished insights for stakeholders to upkeep their position and...

at 19:10
Cancer Immunotherapy Market ? Scope of the Study This report provides forecasts and analysis of the cancer immunotherapy market. This exclusive study also offers analytical data for the historical period (2016-2019) along with forecasts from 2020 to...

at 19:05
Basal Cell Carcinoma Treatment Market ? Scope of the Study The analyst, in its exclusive research report on the basal cell carcinoma treatment market, highlights actionable insights and winning imperatives for stakeholders. This comprehensive study...

at 19:00
a-Si X-ray Flat Panel Detectors Market ? Scope of the Study The analyst, in its exclusive research report on the a-Si x-ray flat panel detectors market, highlights actionable insights and winning imperatives for stakeholders. This comprehensive...



News published on 24 january 2020 at 03:00 and distributed by: